Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib works in treating participants with untreated
high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Pharmacyclics LLC.